Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) announced four abstracts will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting from April 2 to April 7. These abstracts highlight STS101, a novel nasal powder formulation of dihydroergotamine for migraine treatment. Key presentations include pharmacokinetics, long-term safety, and cardiovascular safety data. Satsuma aims to address limitations of existing treatments through improved administration and efficacy. Full abstracts are accessible on the AAN website.
- Four abstracts selected for presentation at the 2022 AAN Annual Meeting, showcasing STS101's features.
- STS101 aims to improve migraine treatment with a novel nasal powder formulation, promising faster absorption and convenience.
- Pending FDA approval for STS101 may delay market entry.
- Uncertainties regarding the efficacy and safety outcomes in ongoing clinical trials.
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that four abstracts highlighting STS101 and its differentiating features were selected for presentation and will be shared at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2 to April 7, 2022. Full abstracts are now available on the AAN website.
| Title: | Pharmacokinetics and Safety of STS101, A Novel Investigational DHE Powder Drug-Device Combination in Healthy Subjects |
| Abstract: | 521 |
| Poster Presentation #: | P13.2-003 |
| Session: | P13: Headache: Migraine Therapeutics 3 |
| Time: | Wednesday April 6, 2022 from 8:00 am – 9:00 am Pacific Time |
| -- | |
Title: | Pharmacokinetic Comparison Of STS101 (A Novel Investigational DHE Nasal Powder) with Liquid Nasal, Injectable and Oral Inhaled DHE Formulations |
| Abstract: | 516 |
| Poster Presentation #: | P13.2-004 |
| Session: | P13: Headache: Migraine Therapeutics 3 |
| Time: | Wednesday April 6, 2022 from 8:00 am – 9:00 am Pacific Time |
| -- | |
| Title: | Long-Term Safety and Tolerability of STS101, A Novel Investigational Dihydroergotamine Nasal Powder: Initial Data from the ASCEND Study |
| Abstract: | 520 |
| Poster Presentation #: | P13.2-002 |
| Session: | P13: Headache: Migraine Therapeutics 3 |
| Time: | Wednesday April 6, 2022 from 8:00 am – 9:00 am Pacific Time |
| -- | |
| Title: | Cardiovascular Safety of STS101, A Novel Investigational DHE Nasal Powder Product: Initial Data from the ASCEND Study |
| Abstract: | 517 |
| Poster Presentation #: | P14.2-006 |
| Session: | P14: Headache: Migraine Therapeutics 4 |
| Time: | Wednesday April 6, 2022 from 11:45 am – 12:45 pm Pacific Time |
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained plasma levels over time with low dose to dose variability. STS101 also now incorporates an improved second-generation nasal delivery device designed to provide more consistent nasal dosing, irrespective of user administration technique. Although DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration processes and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring a compact and convenient dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and expectations for its business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about the Company’s expectations regarding the potential safety and efficacy of STS101, the potential results of the ASCEND and SUMMIT trials, the timing of initiation and data readouts for ongoing and planned clinical trials, the anticipated timing for a potential NDA filing of STS-101, the potential for STS-101 to be an important and differentiated acute treatment option, and the expected cash runway of the Company. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of STS101; the results of preclinical and clinical studies may not be predictive of future results; and the risk that the COVID-19 worldwide pandemic may negatively impact the Company’s business, operations, clinical trials or ability to raise capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release discusses STS101, a product candidate that is in clinical development, and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of STS101 for the therapeutic use for which STS101 is being studied.
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com
FAQ
What is STS101 and its significance for Satsuma Pharmaceuticals (STSA)?
When will Satsuma present STS101 at the AAN Annual Meeting?
What are the main focuses of the abstracts presented by Satsuma Pharmaceuticals (STSA)?
What challenges does STS101 face regarding market release?
How does STS101 compare to existing migraine treatment options?
